Clinical Trial Update: A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating VX-445/tezosacaftor/ivacaftor in cystic fibrosis patients homozygous for F508del has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-445/Tezacaftor/Ivacaftor (VX-445/tezacaftor/ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2021-08-18